{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:32:20Z","timestamp":1788046340098,"version":"build-2784847793"},"reference-count":31,"publisher":"Harborside Press, LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with a 5-year overall survival rate of 10%. In November 2018, NCCN recommended that all patients with PDAC receive genetic counseling (GC) and germline testing regardless of family history. We hypothesized that patients with PDAC were more likely to be referred for testing after this change to the guidelines, regardless of presumed predictive factors, and that compliance would be further improved following the implementation of a hereditary cancer clinic (HCC). <jats:bold>Methods:<\/jats:bold> We conducted a single-institution retrospective analysis of patients diagnosed with PDAC from June 2017 through December 2021 at University of California, Irvine. We compared rates of genetics referral among patients in different diagnostic eras: the 18-month period before the NCCN Guideline change (pre-NCCN era: June 2017 through November 2018), 14 months following the change (post-NCCN era: December 2018 through January 2020), and 18 months after the creation of an HCC (HCC era: June 2020 through December 2021). Family and personal cancer history, genetics referral patterns, and results of GC were recorded. Data were compared using chi-square, Fisher exact, and multivariate analyses. <jats:bold>Results:<\/jats:bold> A total of 335 patients were treated for PDAC (123 pre-NCCN, 109 post-NCCN, and 103 HCC) at University of California, Irvine. Demographics across groups were comparable. Prior to the guideline changes, 30% were referred to GC compared with 54.7% in the post-NCCN era. After the implementation of the HCC, 77.4% were referred to GC (<jats:italic>P<\/jats:italic>&lt;.0001). The odds ratio (OR) for referral to GC among patients with a positive family history of cancer progressively decreased following the change (pre-NCCN era: OR, 11.90 [95% CI, 3.00\u201380.14]; post-NCCN era: OR, 3.39 [95% CI, 1.13\u201310.76]; HCC era: OR, 3.11 [95% CI, 0.95\u201310.16]). <jats:bold>Conclusions:<\/jats:bold> The 2018 updates to the NCCN Guidelines for PDAC recommending germline testing for all patients with PDAC significantly increased GC referral rates at our academic medical center. Implementation of an HCC further boosted compliance with guidelines.<\/jats:p>","DOI":"10.6004\/jnccn.2023.7333","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T17:14:25Z","timestamp":1718730865000},"page":"299-305","source":"Crossref","is-referenced-by-count":10,"title":["Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer"],"prefix":"10.6004","volume":"22","author":[{"given":"Claudia","family":"Rosso","sequence":"first","affiliation":[{"name":"School of Medicine, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomie Devico","family":"Marciano","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Nathan","sequence":"additional","affiliation":[{"name":"Division of Genetic and Genomic Medicine, Department of Pediatrics, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Pin","family":"Chen","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"McLaren","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Osann","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela L.","family":"Flodman","sequence":"additional","affiliation":[{"name":"Division of Genetic and Genomic Medicine, Department of Pediatrics, University of California, Irvine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May T.","family":"Cho","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, UCI School of Medicine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fa-Chyi","family":"Lee","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, UCI School of Medicine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshid","family":"Dayyani","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, UCI School of Medicine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Zell","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, UCI School of Medicine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Valerin","sequence":"additional","affiliation":[{"name":"Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA"},{"name":"Division of Hematology\/Oncology, Department of Medicine, UCI School of Medicine, Irvine, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Gastroenterology","first-page":"1076","article-title":"Hereditary pancreatic cancer","volume":"139","author":"Grover S","year":"2010","unstructured":"Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology 2010;139:1076\u20131080.e2."},{"key":"B2","series-title":"Clin Cancer Res","first-page":"1385","article-title":"Germline DNA sequencing reveals novel mutations predictive of overall survival in a cohort of patients with pancreatic cancer","volume":"26","author":"Goldstein JB","year":"2020","unstructured":"Goldstein JB, Zhao L, Wang X,  Germline DNA sequencing reveals novel mutations predictive of overall survival in a cohort of patients with pancreatic cancer. Clin Cancer Res 2020;26:1385\u20131394."},{"key":"B3","article-title":"NCCN Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic","author":"Daly MB","unstructured":"Daly MB, Pal T, AlHilli Z,  NCCN Clinical Practice Guidelines in Oncology: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2024. Accessed February 15, 2024. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B4","article-title":"NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma","author":"Tempero MA","unstructured":"Tempero MA, Malafa MP, Benson AB III,  NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2024. Accessed February 15, 2024. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B5","series-title":"Lab Med","first-page":"e1","article-title":"Compliance with the current NCCN Guidelines and its critical role in pancreatic adenocarcinoma","volume":"54","author":"Petersen JM","year":"2023","unstructured":"Petersen JM, Jhala DN. Compliance with the current NCCN Guidelines and its critical role in pancreatic adenocarcinoma. Lab Med 2023;54:e1\u20139."},{"key":"B6","series-title":"Br J Cancer","first-page":"1132","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan T","year":"2014","unstructured":"Golan T, Kanji ZS, Epelbaum R,  Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 2014;111:1132\u20131138."},{"key":"B7","series-title":"World J Surg Oncol","first-page":"11","article-title":"Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution","volume":"20","author":"Li Q","year":"2022","unstructured":"Li Q, Feng Z, Miao R,  Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution. World J Surg Oncol 2022;20:11."},{"key":"B8","series-title":"Oncotarget","first-page":"73240","article-title":"Germline mutations in pancreatic cancer and potential new therapeutic options","volume":"8","author":"Pihlak R","year":"2017","unstructured":"Pihlak R, Valle JW, McNamara MG. Germline mutations in pancreatic cancer and potential new therapeutic options. Oncotarget 2017;8:73240\u201373257."},{"key":"B9","series-title":"ESMO Open","first-page":"e000578","article-title":"Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies","volume":"5","author":"Pokataev I","year":"2020","unstructured":"Pokataev I, Fedyanin M, Polyanskaya E,  Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies. ESMO Open 2020;5:e000578."},{"key":"B10","series-title":"N Engl J Med","first-page":"317","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan T","year":"2019","unstructured":"Golan T, Hammel P, Reni M,  Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019;381:317\u2013327."},{"key":"B11","series-title":"Cancer Discov","first-page":"620","article-title":"Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers","volume":"7","author":"de Bono J","year":"2017","unstructured":"de Bono J, Ramanathan RK, Mina L,  Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1\/2 mutations and selected sporadic cancers. Cancer Discov 2017;7:620\u2013629."},{"key":"B12","series-title":"Br J Cancer","first-page":"1321","article-title":"BRCA-mutant pancreatic ductal adenocarcinoma","volume":"125","author":"Lai E","year":"2021","unstructured":"Lai E, Ziranu P, Spanu D,  BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer 2021;125:1321\u20131332."},{"key":"B13","series-title":"JAMA Oncol","first-page":"1","article-title":"Ipilimumab\/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants","volume":"8","author":"Terrero G","year":"2022","unstructured":"Terrero G, Datta J, Dennison J,  Ipilimumab\/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol 2022;8:1\u20133."},{"key":"B14","series-title":"Front Digit Health","first-page":"961128","article-title":"Barriers, interventions, and recommendations: improving the genetic testing landscape","volume":"4","author":"Dusic EJ","year":"2022","unstructured":"Dusic EJ, Theoryn T, Wang C,  Barriers, interventions, and recommendations: improving the genetic testing landscape. Front Digit Health 2022;4:961128."},{"key":"B15","series-title":"Oncologist","first-page":"e1982","article-title":"Implementation of an embedded in-clinic genetic testing station to optimize germline testing for patients with pancreatic adenocarcinoma","volume":"26","author":"Walker EJ","year":"2021","unstructured":"Walker EJ, Goldberg D, Gordon KM,  Implementation of an embedded in-clinic genetic testing station to optimize germline testing for patients with pancreatic adenocarcinoma. Oncologist 2021;26:e1982\u20131991."},{"key":"B16","series-title":"J Cancer Educ","first-page":"362","article-title":"Knowledge, attitudes, willingness to pay, and patient preferences about genetic testing and subsequent risk management for cancer prevention","volume":"37","author":"Guo F","year":"2022","unstructured":"Guo F, Hirth JM, Fuchs EL,  Knowledge, attitudes, willingness to pay, and patient preferences about genetic testing and subsequent risk management for cancer prevention. J Cancer Educ 2022;37:362\u2013369."},{"key":"B17","series-title":"J Clin Oncol","first-page":"3382","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","author":"Shindo K","year":"2017","unstructured":"Shindo K, Yu J, Suenaga M,  Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol 2017;35:3382\u20133390."},{"key":"B18","article-title":"NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma","author":"Tempero MA","unstructured":"Tempero MA, Malafa MP, Chiorean EG,  NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2019. Accessed February 15, 2021. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B19","series-title":"J Genet Couns","first-page":"645","article-title":"Report from the National Society of Genetic Counselors service delivery model task force: a proposal to define models, components, and modes of referral","volume":"21","author":"Cohen SA","year":"2012","unstructured":"Cohen SA, Gustafson SL, Marvin ML,  Report from the National Society of Genetic Counselors service delivery model task force: a proposal to define models, components, and modes of referral. J Genet Couns 2012;21:645\u2013651."},{"key":"B20","series-title":"J Genet Couns","first-page":"283","article-title":"Genetic counseling service delivery models: a study of genetic counselors\u2019 interests, needs, and barriers to implementation","volume":"30","author":"Boothe E","year":"2021","unstructured":"Boothe E, Greenberg S, Delaney CL,  Genetic counseling service delivery models: a study of genetic counselors\u2019 interests, needs, and barriers to implementation. J Genet Couns 2021;30:283\u2013292."},{"key":"B21","series-title":"Fam Cancer","first-page":"91","article-title":"Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake","volume":"22","author":"Ramsey ML","year":"2023","unstructured":"Ramsey ML, Tomlinson J, Pearlman R,  Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Fam Cancer 2023;22:91\u201397."},{"key":"B22","series-title":"Oncologist","first-page":"486","article-title":"Adherence to NCCN genetic testing guidelines in pancreatic cancer and impact on treatment","volume":"28","author":"Crowley F","year":"2023","unstructured":"Crowley F, Gandhi S, Rudshteyn M,  Adherence to NCCN genetic testing guidelines in pancreatic cancer and impact on treatment. Oncologist 2023;28:486\u2013493."},{"key":"B23","series-title":"BMC Health Serv Res","first-page":"165","article-title":"Impact of a genetic counseling requirement prior to genetic testing","volume":"18","author":"Stenehjem DD","year":"2018","unstructured":"Stenehjem DD, Au T, Sainski AM,  Impact of a genetic counseling requirement prior to genetic testing. BMC Health Serv Res 2018;18:165."},{"key":"B24","series-title":"JCO Oncol Pract","first-page":"e236","article-title":"Implementing systematic genetic counseling and multigene germline testing for individuals with pancreatic cancer","volume":"17","author":"Chittenden A","year":"2021","unstructured":"Chittenden A, Haraldsdottir S, Ukaegbu C,  Implementing systematic genetic counseling and multigene germline testing for individuals with pancreatic cancer. JCO Oncol Pract 2021;17:e236\u2013247."},{"key":"B25","series-title":"Clin Transl Gastroenterol","first-page":"e00414","article-title":"Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study","volume":"12","author":"Uson PLS Jr","year":"2021","unstructured":"Uson PLS Jr, Samadder NJ, Riegert-Johnson D,  Clinical impact of pathogenic germline variants in pancreatic cancer: results from a multicenter, prospective, universal genetic testing study. Clin Transl Gastroenterol 2021;12:e00414."},{"key":"B26","series-title":"World J Gastroenterol","first-page":"6515","article-title":"Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance","volume":"27","author":"Mart\u00ednez-Gal\u00e1n J","year":"2021","unstructured":"Mart\u00ednez-Gal\u00e1n J, Rodriguez I, Caba O. Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance. World J Gastroenterol 2021;27:6515\u20136521."},{"key":"B27","series-title":"J Clin Oncol","first-page":"3929","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler HL","year":"2022","unstructured":"Kindler HL, Hammel P, Reni M,  Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol 2022;40:3929\u20133939."},{"key":"B28","series-title":"Sci Rep","first-page":"7048","article-title":"Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study","volume":"10","author":"Wang H","year":"2020","unstructured":"Wang H, Liu J, Xia G,  Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study. Sci Rep 2020;10:7048."},{"key":"B29","series-title":"Cancers (Basel)","first-page":"4430","article-title":"Prevalence of germline pathogenic variants in cancer predisposing genes in Czech and Belgian pancreatic cancer patients","volume":"13","author":"Wieme G","year":"2021","unstructured":"Wieme G, Kral J, Rosseel T,  Prevalence of germline pathogenic variants in cancer predisposing genes in Czech and Belgian pancreatic cancer patients. Cancers (Basel) 2021;13:4430."},{"key":"B30","series-title":"Clin Cancer Res","first-page":"3239","article-title":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","volume":"26","author":"Park W","year":"2020","unstructured":"Park W, Chen J, Chou JF,  Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res 2020;26:3239\u20133247."},{"key":"B31","series-title":"Genet Med","first-page":"428","article-title":"Trends in utilization and costs of BRCA testing among women aged 18\u201364 years in the United States, 2003\u20132014","volume":"20","author":"Chen Z","year":"2018","unstructured":"Chen Z, Kolor K, Grosse SD,  Trends in utilization and costs of BRCA testing among women aged 18\u201364 years in the United States, 2003\u20132014. Genet Med 2018;20:428\u2013434."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/5\/article-p299.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/5\/article-p299.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/5\/article-p299.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T15:42:29Z","timestamp":1722008549000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/5\/article-p299.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7333","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}